3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
13
Breast Neoplasms
11
Carcinoma, Transitional Cell
6
Carcinoma, Non-Small-Cell Lung
5
Urinary Bladder Neoplasms
4
Neoplasm Metastasis
4
Lung Neoplasms
3
Small Cell Lung Carcinoma
2
Urothelial Bladder Carcinoma
1
Salivary Gland Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Metastatic Urothelial Cancer
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Localized Muscle Invasive Bladder Urothelial Carcinoma
1
Liver Failure
1
HRD Cancer
1
Glioblastoma
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Carcinoma, Small Cell
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
Pemetrexed
4
Spinal Puncture
3
Radiotherapy
3
aflutinib
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Bevacizumab
2
toripalimab
1
sintilimab
1
pertuzumab
1
lorlatinib
1
azeliragon
1
adavosertib
1
Trastuzumab
1
Referral and Consultation
1
Radiation
1
Physical Examination
1
Immunotherapy, Adoptive
1
Immune Checkpoint Inhibitors
1
GDC-0084
1
Drug Therapy
1
Deferoxamine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Meningeal Carcinomatosis
×
sacituzumab govitecan
×
90 days
×
Clear all
No trials found.